Liquid Biopsy Markets, 2029 - Exploring Screening, Diagnostic, and Therapy Selection Opportunities
Explore the evolving landscape of cancer diagnostics with our comprehensive report, analyzing screening, diagnostic, and therapy selection markets. Discover potential growth by cancer type and region, with insights into circulating tumor cells, cell-free DNA, and exosomes. Forecasts and valuations empower informed decisions.
Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029" has been added to ResearchAndMarkets.com's offering.
Explore the dynamic landscape of the Screening, Diagnostic, Therapy Selection, Minimal Residual Disease, and Screening Market through our comprehensive report, which provides a detailed analysis of price and volume outlooks across different types of cancer.
Discover the transformative advancements in cancer diagnostics, particularly the innovative use of in vitro blood testing to detect cancer DNA, paving the way for widespread cancer screening tests. This cutting-edge technology is advancing rapidly, outpacing market growth, and offers a less invasive alternative to traditional surgical biopsies, poised to revolutionize disease diagnosis and monitoring.
The report delves into the growth phase of the market, offering insights into its substantial impact on the healthcare industry. It includes a five-year forecast of market size expansion, with detailed projections segmented by country, cancer type, and usage categories-ranging from screening, diagnosis, therapy selection, to recurrence monitoring.
Our analysis provides a granular breakdown for 15 countries and 4 regions, alongside specific insights on cancers such as Lung, Breast, Colorectal, Prostate, Cervical, and others. It also explores opportunities and challenges within screening, early detection, diagnostic, therapy monitoring, and recurrence monitoring realms, equipping stakeholders with essential knowledge for making informed investment decisions and accurate market valuations.
Capitalizing on the exhaustive market intelligence contained within, this report empowers decision-makers to confidently navigate the evolving cancer diagnostics landscape, leveraging unprecedented technological advancements to enhance patient outcomes and streamline healthcare processes.
Key Topics Covered:
1 Market Guides1.1 Liquid Biopsy Market - Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors1.4 Impact of Artificial Intelligence on Liquid Biopsy Market2 Introduction and Market Definition2.1 What is Liquid Biopsy?2.2 The Sequencing Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry3 Market Overview3.1 Players in a Dynamic Market3.2 Using Biopsies3.3 Biopsy Sites3.4 The Situation Today - Biopsy Analysis3.5 Evidence of Cancer - Liquid Biopsy Technology3.6 Cancer Treatment Protocol Under Siege3.7 Structure of Industry Plays a Part4 Market Trends4.1 Factors Driving Growth4.1.1 Non-Invasive Game Changer4.1.2 Lower Cost4.1.3 Greater Accuracy4.1.4 Wide Range of Potential Uses4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 Lower prices4.2.2 Lack of Standards4.2.3 Protocol Resistance4.2.4 Initial Adoption Cost4.2.5 Conclusion4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Impact of NGS on pricing4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay5 Liquid Biopsy Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Liquid Biopsy Firm QCDx Closes Financing5.3 LabCorp Launches Liquid Biopsy5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform5.7 Syantra Closes Financing5.8 Concerns Over Grail Test Effectiveness5.9 Guardant Health Sues Tempus for Patent Infringement5.10 Delfi Dx Liquid Biopsy Technology Shows Promise5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx5.12 Grail Details TBE Method for Cancer Monitoring5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage5.14 Personalis NeXT Personal Dx Early-Access Program5.15 Liquid Biopsy Shortens Time to Treatment5.16 Guardant Health MRD Test Garners Coverage5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test5.21 Sophia Genetics to Commercialize Liquid Biopsy Test5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform5.25 PamGene Expanding Liquid Biopsy Assays5.26 Liquid Biopsy Firm Hedera Dx Raises €14M5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx5.28 Precision Oncology Dx Access Varies Widely in Europe5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy5.31 BillionToOne Launches First Liquid Biopsy Products5.32 Dxcover Advances Multicancer Detection Platform5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test5.34 Illumina Sues Guardant Health Over Patents5.35 Invitae to Expand Cancer Testing Portfolio5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform5.42 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition5.44 Bio-Techne to Acquire Asuragen for up to $320M5.45 Personalis Broadens Liquid Biopsy Offering5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response5.49 Liquid Biopsy NGS Panels - Diverse Test Claims5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays5.51 Natera Liquid Biopsy Test Coverage to Expand5.52 Freenome Closes Financing to Support Early Cancer Detection Trial5.53 C$2.6M Liquid Biopsy Initiative5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy5.55 Liquid Biopsy Shows Promise as Screen for Cancers5.56 Inivata launches RaDaRT for the detection of residual disease and recurrence5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy6 Profiles of Key Players6.1 Admera Health, LLC6.2 Abbott Laboratories6.3 AccuraGen Inc.6.4 Acuamark Diagnostics6.5 Agilent6.6 Amoy Diagnostics Co., Ltd.6.7 Anchor Dx6.8 ANGLE plc6.9 Applied DNA Sciences6.10 ARUP Laboratories6.11 AVIVA Systems Biology6.12 Baylor Miraca Genetics Laboratories6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Berkley Lights6.16 BGI Genomics Co. Ltd6.17 BillionToOne6.18 Bioarray Genetics6.19 Biocartis6.20 Biocept, Inc.6.21 Biodesix Inc.6.22 BioFluidica6.23 Biolidics Ltd6.24 bioMerieux Diagnostics6.25 Bioneer Corporation6.26 Bio-Rad Laboratories, Inc6.27 Bio-Techne6.28 Bioview6.29 Burning Rock6.30 Cardiff Oncology6.31 CareDx6.32 Caris Molecular Diagnostics6.33 CellCarta6.34 CellMax Life6.35 Cepheid (Danaher)6.36 Circulogene6.37 Cizzle Biotech6.38 Clearbridge Biomedics6.39 Clinical Genomics6.40 Cytolumina Technologies Corp.6.41 Datar Cancer Genetics Limited6.42 Diagnologix LLC6.43 Dxcover6.44 Element Biosciences6.45 Enzo Biochem6.46 Epic Sciences6.47 Epigenomics AG6.48 Eurofins Scientific6.49 Exact Sciences6.50 Fluxion Biosciences (Cell Microsystems)6.51 Freenome6.52 Fyr Diagnostics6.53 GeneFirst Ltd.6.54 Genetron Holdings6.55 GILUPI Nanomedizin6.56 Guardant Health6.57 HansaBiomed6.58 Haystack Oncology (Quest Dx)6.59 iCellate6.60 ICON PLC6.61 Illumina6.62 Incell Dx6.63 Inivata6.64 INOVIQ6.65 Invitae Corporation6.66 J&J Innovative Medicine6.67 Lucence Health6.68 Lunglife AI Inc6.69 MDNA Life SCIENCES, Inc.6.70 MDx Health6.71 Menarini Silicon Biosystems6.72 Mesa Laboratories, Inc.6.73 Millipore Sigma6.74 Miltenyi Biotec6.75 miR Scientific6.76 Myriad Genetics6.77 Nanostring6.78 NantHealth, Inc.6.79 Natera6.80 NeoGenomics6.81 Novogene6.82 On-Chip Biotechnologies6.83 Oncocyte6.84 OncoDNA6.85 Oncimmune6.86 Oxford Nanopore Technologies6.87 PamGene6.88 Panagene6.89 Personalis6.90 PGDx (Labcorp)6.91 PrecisionMed6.92 Predicine6.93 Predictive Oncology6.94 Prenetics6.95 Promega6.96 Qiagen6.97 Rarecells SAS6.98 RareCyte6.99 Revvity6.100 Roche Diagnostics6.101 Saga Diagnostics6.102 Screencell6.103 Siemens Healthineers6.104 simfo GmbH6.105 Singlera Genomics Inc.6.106 Singular Genomics6.107 Standard BioTools6.108 Stilla Technologies6.109 Superfluid Dx6.110 Sysmex Inostics6.111 Tempus Labs, Inc.6.112 Thermo Fisher Scientific6.113 Todos Medical6.114 Ultima Genomics6.115 Veracyte6.116 VolitionRX6.117 Vortex Biosciences7 The Global Market for Liquid Biopsy Diagnostics7.1 Global Market Overview by Country7.2 Global Market by Cancer - Overview7.3 Global Market by Usage - Overview7.4 Global Market by Place - Overview7.5 Global Market by Marker - Overview7.6 Global Market by Product - Overview8 Global Liquid Biopsy Diagnostic Markets - By Cancer8.1 Breast8.2 Colorectal8.3 Cervical8.4 Lung8.5 Prostate9 Global Liquid Biopsy Diagnostic Markets - by Usage9.1 Screening9.3 Diagnostic9.4 Therapy9.5 Monitor10 Global Liquid Biopsy Diagnostic Markets - by Place10.1 Hospital Lab10.2 Lab Service10.3 Lab Outpatient11 Global Liquid Biopsy Diagnostic Markets - by Marker11.1 Circulating Tumor Cell11.2 Cell Free DNA11.3 Vesicle12 Global Liquid Biopsy Diagnostic Markets - by Product12.1 Kits12.2 Instruments12.3 Service13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule
For more information about this report visit https://www.researchandmarkets.com/r/wtlj66
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token
By GlobeNewswire Published on June 15, 2025, 13:20 IST SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) — Vaultro Finance has just announced a landmark achievement in its public sale of the native utility token VLT. The $VLT presale Round has now achieved a 50% sale milestone, marking a pivotal moment in the project's journey and sending a clear signal that investor demand is surging. Achieving half of the targeted hardcap in rapid fashion underscores the market's enthusiasm for Vaultro's revolutionary approach to decentralized index fund investing on the XRP Ledger. Purchase $VLT Token on Presale Round This breakthrough comes amid a broader upswing for XRP itself. The token continues to trade above $2.10, supported by growing institutional inflows and the expanding suite of XRP based exchange traded products worldwide. Regulatory headwinds have given way to clarity, and major markets are embracing XRP infrastructure. In this revitalized environment, Vaultro Finance stands out by delivering real world utility in the form of a fully on chain index fund protocol. The $VLT Token Presale milestone of 50% claimed demonstrates that investors are seeking projects which combine familiar financial logic with the transparency and efficiency of blockchain. At the heart of the Vaultro ecosystem is the VLT token , VLT holders unlock rights that extend far beyond simple token ownership. They gain the ability to create their own custom index funds, selecting themes such as artificial intelligence tokens, stablecoins for stability, decentralized finance protocols capturing the next wave of innovation, and high potential XRPL assets. VLT token holders also participate directly in governance, voting on platform upgrades, new fund listings, and strategic decisions that shape the protocol's future. Participate in $VLT Presale at Discount Rate Participation in the presale remains open but is advancing toward its halfway point. Prospective contributors must hold an XRP native wallet and set up a trustline for the VLT token by following the step by step guideline, A minimum contribution of 200 XRP ensures broad accessibility. The official presale portal at is available now for anyone ready to join. Do not miss your chance to be part of the next wave of decentralized finance on the XRP Ledger. Secure your VLT tokens today and help define the future of on chain index fund management. For more details on Vaultro Finance and the $VLT presale visit; Website Join $VLT Presale X fka Twitter Telegram Community Whitepaper Blog Channel Contact:Lee Wang [email protected] Disclaimer: This is a paid post and is provided by Vaultro Finance. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
4 hours ago
- Business Upturn
Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap
By GlobeNewswire Published on June 15, 2025, 15:45 IST TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) — Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch now just weeks away. With over $4.5 million already raised and more than 11,500 participants onboard, momentum is surging. Final Opportunity Before Public Launch The presale is currently in Phase 7's last day , with BTC-S tokens priced at $7. The next presale phase will raise the price to $8, with a launch price set at $20. This structured pricing reflects strong demand and limited availability, given the project's fixed supply of 21 million tokens—identical in scarcity to the original Bitcoin. With fewer than eight weeks remaining before public launch, this is the last opportunity for early supporters to participate before BTC-S becomes tradable on major platforms. A Scarcity-Driven Token Built for Scalability Bitcoin Solaris takes the best parts of Bitcoin, the 21 million supply cap, and upgrades everything else. While Bitcoin transactions take about 10 minutes to finalize, Bitcoin Solaris pushes blocks every 15 seconds and confirms them in under 2 seconds. This performance comes from a hybrid structure that combines a Proof-of-Work Base Layer with a high-throughput Delegated Proof-of-Stake Solaris Layer. This dual-consensus model: Supports 10,000+ TPS Slashes energy usage by over 99.95% compared to Bitcoin Enables lightning-fast smart contract execution Rotates validators based on weighted contribution and uptime It's the kind of blockchain performance that fits perfectly in a bull market narrative—fast, efficient, and decentralized. A Smarter, Faster, Fairer Bitcoin Is Here—Step Into BTC-S Tokenomics That Ignite Long-Term Demand Beyond the tech, Bitcoin Solaris backs its vision with powerful tokenomics. The hard cap of 21 million BTC-S tokens mirrors Bitcoin's scarcity, but the utility goes far beyond holding. Here's how the tokenomics create upward pressure: Tokens are required for staking, validating, and interacting with the ecosystem Time-weighted validator rewards encourage long-term holding No inflationary print cycles—only mined or earned tokens The low total supply paired with strong use cases builds consistent demand BTC-S isn't just another asset to flip, it's a network to participate in. Referral-Driven Growth Fueling Viral Expansion Bitcoin Solaris's Double Rewards Referral Program is a major catalyst behind its exponential community growth. Here's how it works: Anyone who refers new investors earns 5% of their purchases in BTC-S tokens New users who join via a referral also get 5% bonus tokens All rewards are credited automatically via the user dashboard on This viral mechanic has powered over 11,500 users to join the presale in just weeks, turning BTC-S into one of the fastest-growing ecosystems of this cycle. The community is now spreading across Telegram and X , further accelerating its altcoin season momentum. Presale Is Almost Over: The Window Is Closing A detailed video review by 2Bit Crypto breaks down exactly why BTC-S is gaining this much traction—including its audit-approved smart contracts and high-performance infrastructure. The Engine of Wealth in Altcoin Season What sets Bitcoin Solaris apart in this altcoin season isn't just hype—it's architecture. By allowing anyone to participate in mining from a laptop , browser, or upcoming mobile platform, it reduces barriers for earning crypto at scale. Its validator reward structure balances decentralization and speed. Blocks are mined via Proof-of-Work, then delegated for verification in a DPoS layer with built-in slashing and validator rotation. This ensures fair payouts, lower risks, and a healthy ecosystem long-term. Add in audits from Cyberscope and Freshcoins , and you've got one of the most technically complete altcoins on the rise. Conclusion Altcoin season is known for turning obscure projects into household names. With Bitcoin Solaris, we're watching that transformation in real time. It blends Bitcoin's scarcity with elite performance, DeFi-ready tokenomics, and viral growth mechanics. As the presale comes to a close, BTC-S is looking more and more like the best coin of this cycle. For more information on Bitcoin Solaris: Website: Telegram: X: Media Contact:Xander Levine [email protected] Press Kit: Available upon request Disclaimer: This is a paid post and is provided by Bitcoin Solaris . The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
4 hours ago
- Business Upturn
Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs1 Advertisement BEERSE, BELGIUM, June 15, 2025 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson company, announced today new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY®▼(talquetamab), the first European Commission (EC) approved GPRC5D-directed bispecific antibody, and TECVAYLI®▼(teclistamab), the first EC approved BCMA-directed bispecific antibody. The results show a high overall response rate (ORR) with durability in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who have true extramedullary disease (EMD).1 EMD is defined as soft tissue/organ-associated plasmacytomas with no contact to bony structures as per International Myeloma Working Group (IMWG) criteria.2 RedirecTT-1 is the largest study dedicated to patients with EMD to date.1 These data were featured in a late-breaking oral presentation (Abstract #LB4001) at the 2025 European Hematology Association (EHA) Congress.1 EMD represents an aggressive form of multiple myeloma and occurs when myeloma cells spread and form tumours (plasmacytomas) elsewhere in the body, such as in soft tissues and organs.3 These patients often face limited treatment options and worse outcomes due to the complexity of the disease, including tumour heterogeneity, resulting in low ORRs and rapid relapses with current standard therapies.2,3 On average, TCE RRMM patients with EMD have an ORR of less than 40 percent and a median progression-free survival (PFS) of less than six months.4 'The investigational combination of talquetamab and teclistamab has demonstrated deep, durable responses in patients with relapsed or refractory multiple myeloma, and now shows great promise in those with extramedullary myeloma, where standard therapies often fall short,' said Yael Cohen, M.D., Head of Myeloma Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.* 'Dual targeting of GPRC5D and BCMA may lead to a higher ORR and greater depth of response by mitigating target antigen-related escape. The RedirecTT-1 trial shows the power of this novel dual-targeting combination approach as a potential treatment option for patients with this disease.' The Phase 2 RedirecTT-1 study enrolled 90 patients with TCE RRMM with true EMD.1 Of these patients, 84.4 percent were triple-class refractory, 35.6 percent were penta-drug refractory, 20.0 percent had previously received BCMA CAR-T therapy, and 8.9 percent had previously received a bispecific antibody.1 The investigational combination of talquetamab and teclistamab led to a high ORR of 78.9 percent (95 percent confidence interval [CI]; 69.0–86.8), with more than half of patients (54.4 percent) achieving complete response or better.1 High responses were observed even in patients exposed to prior BCMA CAR-T or anti-FcRH5 bispecific antibodies (83.3 percent ORR; 58.6-96.4 and 75.0 percent ORR; 34.9-96.8, respectively).1 Among responders, 66.2 percent remained in response at the data cutoff, with a median follow-up of 13.4 months, signalling deep and durable responses.1 Treatment with the combination resulted in 61.0 percent of patients progression-free and alive at one year.1 Additionally, the combination led to durable responses, with 64.1 percent of patients maintaining response (median duration of response: 13.8 months) and 74.5 percent of patients alive at one year, while median overall survival was not yet reached.1 'Multiple myeloma remains a complex and heterogeneous disease, with extramedullary disease presenting a particularly aggressive and challenging to treat form,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology at Johnson & Johnson Innovative Medicine. 'The RedirecTT-1 study reflects our strategy to harness novel mechanisms of action, such as the combination of these dual bispecific antibodies, to help redefine potential outcomes for subsets of patients who are currently faced with a poor prognosis and limited options.' The safety profile of the combination was consistent with previous reports of talquetamab and teclistamab as monotherapies, with no new safety signals identified.1 Patients were given the option to switch to once a month dosing potentially contributing to improved tolerability.1 Rates of discontinuation were low with the treatment combination of talquetamab and teclistamab due to adverse events (AEs).1 Four participants discontinued talquetamab only.1 Reports of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade.1 Of the ten patients who had Grade 5 AEs (11.1 percent), five were due to infections.1 There were five patient deaths due to infection and the rates of severe infection were similar to those observed with some BCMA bispecific antibody monotherapies.1 'Patients with extramedullary myeloma, especially those who have exhausted prior therapies, need more effective treatment options,' said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine. 'Our first-in-class bispecific antibodies talquetamab and teclistamab have transformed treatment for relapsed or refractory multiple myeloma. The RedirecTT-1 study underscores our commitment to advancing innovative therapies that attack the disease in different ways by building combinable and complementary regimens.' About Talquetamab Talquetamab received conditional marketing authorisation (CMA) from the European Commission (EC) in August 2023, as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.5 The U.S. Food and Drug Administration (FDA) also granted talquetamab approval in August 2023, for the treatment of adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.6 Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 on the surface of T-cells, and GPRC5D, a novel target which is highly expressed on the surface of multiple myeloma cells, with minimal to no expression detected on B-cells or B-cell precursors.5 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using talquetamab, please refer to the Summary of Product Characteristics. In line with European Medicine Agency (EMA) regulations for new medicines and those given conditional approval, talquetamab is subject to additional monitoring. About Teclistamab Teclistamab received EC approval in August 2022 for the treatment of patients with RRMM who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.7 In August 2023, the EC approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months.8 Teclistamab received approval from the U.S. FDA in October 2022 for the treatment of adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.9 Teclistamab is an off-the-shelf (or ready-to-use) bispecific antibody.9,10 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's immune system to fight the cancer. Teclistamab is currently being evaluated in several combination studies.10,11,12,13,14 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using teclistamab, please refer to the Summary of Product Characteristics. In line with European Medicine Agency (EMA) regulations for new medicines and those given conditional approval, teclistamab is subject to additional monitoring. About Multiple Myeloma Multiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.15,16 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications.15,16 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died.17 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy18,19 while remissions become progressively shorter.18,19,20 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage.21 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at Follow us at Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of teclistamab and talquetamab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. * Yael Cohen, M.D., Head of Myeloma Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel., has provided consulting, advisory and speaking services to Janssen-Cilag International NV; she has not been paid for any media work. ### 1 Kumar S, et al. Phase 2 study of Talquetamab + Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma with Extramedullary Disease: presentation at 2025 European Hematology Association (EHA) Congress; June 12-15, 2025. 2 Ho M, et Multiple Myeloma: Challenges and Opportunities. Curr. Oncol, 2025; 32: 182. 3 Blade J, et al. Extramedullary Disease in Multiple Myeloma: a Systematic Literature Review. Blood Cancer J, 2022; 12(3):45. 4 Moreau P, et al. Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies. Clinical Lymphoma, Myeloma and Leukemia, 2025; 25: S2152-2650. 5 European Medicines Agency. TALVEY Summary of Product Characteristics. Available at: Last accessed: June 2025. 6 FDA. FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma. Available at: Last accessed: June 2025. 7 Janssen Marks First Approval Worldwide. Available at: Last accessed: June 2025. 8 European Commission Approves Reduced Dosing Frequency for Janssen's Bispecific Antibody TECVAYLI®▼ (teclistamab). Available at: Last accessed: June 2025. 9 U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Available at: Last accessed: June 2025. 10 European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: Last accessed: June 2025. 11 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: Last accessed: June 2025. 12 A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: Last accessed: June 2025. 13 A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: Last accessed: June 2025. 14 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (TecDara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: Last accessed: June 2025. 15 Abdi J, et al. Drug Resistance in Multiple Myeloma: Latest Findings on Molecular Mechanisms. Oncotarget 2013;4(12):2186-2207. 16 American Society of Clinical Oncology. Multiple Myeloma: Introduction. Available at: Last accessed: June 2025. 17 ECIS – European Cancer Information System. Estimates of Cancer Incidence and Mortality in 2022, by Country. Multiple Myeloma. Available at: Last accessed: June 2025. 18 Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347. 19 Hernández-Rivas JÁ, et al. The Changing Landscape of Relapsed and/or Refractory Multiple Myeloma (MM): Fundamentals and Controversies. Biomark Res. 2022;10(1):1-23. 20 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430. 21 American Cancer Society. Multiple Myeloma: Early Detection, Diagnosis and Staging. Available at: Last accessed: June 2025. CP-526056 June 2025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
